Cargando…

MEK inhibitors for the treatment of non-small cell lung cancer

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Jing, Liu, Yang, Yang, Sen, Wu, Xuan, Li, Hongle, Wang, Qiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786519/ https://www.ncbi.nlm.nih.gov/pubmed/33402199 http://dx.doi.org/10.1186/s13045-020-01025-7

Ejemplares similares

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
por: Hou, Jiabao, et al.
Publicado: (2022)

MEK inhibitors against MET-amplified non-small cell lung cancer
por: Chiba, Masato, et al.
Publicado: (2016)

Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells
por: Iezzi, Alice, et al.
Publicado: (2018)

Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review
por: Zhang, Zhe, et al.
Publicado: (2021)

Evaluation of the radiosensitizing effect of MEK inhibitor KZ-001 on non-small cell lung cancer cells in vitro
por: Huang, Gongchao, et al.
Publicado: (2023)

Emerging therapies for small cell lung cancer
por: Yang, Sen, et al.
Publicado: (2019)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
por: Haslett, K., et al.
Publicado: (2021)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer
por: Fanini, Francesca, et al.
Publicado: (2021)

Combination of the LARS1 Inhibitor, BC-LI-0186 with a MEK1/2 Inhibitor Enhances the Anti-Tumor Effect in Non–Small Cell Lung Cancer
por: Lee, Sang Hoon, et al.
Publicado: (2023)

Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo
por: Meng, Jieru, et al.
Publicado: (2010)

HER3 expression and MEK activation in non-small-cell lung carcinoma
por: Manickavasagar, Thubeena, et al.
Publicado: (2021)

ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer
por: Liu, Zheng, et al.
Publicado: (2020)

EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in non-small cell lung cancer cells
por: Lin, Chuan, et al.
Publicado: (2018)

Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma
por: Chua, Kian Ngiap, et al.
Publicado: (2015)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019)

Caudatin blocks the proliferation, stemness and glycolysis of non-small cell lung cancer cells through the Raf/MEK/ERK pathway
por: Hou, Juan, et al.
Publicado: (2022)

Echinacoside Induces Mitochondria-Mediated Pyroptosis through Raf/MEK/ERK Signaling in Non-Small Cell Lung Cancer Cells
por: Shi, Ye, et al.
Publicado: (2022)

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
por: Gelsomino, Francesco, et al.
Publicado: (2021)

MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells
por: Jing, Changwen, et al.
Publicado: (2019)

A Novel PDK1/MEK Dual Inhibitor Induces Cytoprotective Autophagy via the PDK1/Akt Signaling Pathway in Non-Small Cell Lung Cancer
por: Liu, Rangru, et al.
Publicado: (2023)

Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer
por: Shrestha, N., et al.
Publicado: (2019)

Discovery of an OTUD3 inhibitor for the treatment of non-small cell lung cancer
por: Zhang, Yonghui, et al.
Publicado: (2023)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
por: Küsters-Vandevelde, Heidi VN, et al.
Publicado: (2014)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

P1097: MEK-INHIBITORS IN TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS
por: Burtsev, E., et al.
Publicado: (2022)

Emerging evidence and treatment paradigm of non-small cell lung cancer
por: Liu, Si-Yang Maggie, et al.
Publicado: (2023)

The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer
por: Zhao, Yuhua, et al.
Publicado: (2023)

HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
por: Han, Shuyan, et al.
Publicado: (2023)

Current treatments for non-small cell lung cancer
por: Guo, Qianqian, et al.
Publicado: (2022)

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis
por: Aaroe, Ashley, et al.
Publicado: (2023)

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
por: Broutin, Sophie, et al.
Publicado: (2016)

The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells
por: Huang, Wen-Chien, et al.
Publicado: (2021)

RET Inhibitors in Non-Small-Cell Lung Cancer
por: Cascetta, Priscilla, et al.
Publicado: (2021)

BRAF Inhibitors in Non-Small Cell Lung Cancer
por: Sforza, Vincenzo, et al.
Publicado: (2022)

Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
por: Lyons, Yasmin A., et al.
Publicado: (2014)

Second- and third-generation ALK inhibitors for non-small cell lung cancer
por: Wu, Jingjing, et al.
Publicado: (2016)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lmgfhnumj71uvpvg58j51l7mnr